Risk-Based Post-Marketing Surveillance (RB-PMS2) of Antimalarial and MNCH drugs in Mali (PY2)
Main Article Content
Abstract
Background and Objectives: The advent of multi-source generic drugs has exacerbated the prevalence of drugs and the spread of counterfeit and sub-standard drugs requiring increased vigilance and collaboration from drug regulatory authorities. Post-marketing surveillance (PMS) of medicines therefore plays an important role in detecting poor quality products on the market. Risk-Based Post-Market Surveillance (RB-PMS) RB-PMS helps optimize resource utilization and create sustainable post-market surveillance programs that are integrated and implemented as a key regulatory function.
Methods: The survey concerned points of sale identified by a Technical Working Group in certain geographical areas according to risk-based approaches applied in the selection of the type of drugs to be targeted. It took place from September to December 2021 and aimed to assess the quality of antimalarial and MNCH medicines.
Results: A total of 320 samples were taken and analyzed according to a risk-based protocol, of which 306 were compliant with a rate of 96% against 14 were non-compliant or 4% (P≤0,05). Non-compliant drugs were from both the public and private sectors. We found that 84% of drugs were unregistered among which antimalarials were the least registered drugs with a rate of 66% against 34% for MNCH drugs and came mainly from India and China.
Conclusion: The RB-PMS allows the optimization of health resources in LMIC. In view of its scientific nature, this sampling and analysis technique must be made permanent to ensure health and guarantee access to quality medicines for the health and well-being of populations.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. World malaria report 2019 [Internet]. [cité 30 déc 2021]. Disponible sur: https://www.who.int/ publications-detail-redirect/9789241565721
II. Mali [Internet]. Severe Malaria Observatory. [cité 30 déc 2021]. Disponible sur: https://www.severemalaria.org/fr/pays/mali
III. INSTAT. ENQUÊTE DÉMOGRAPHIQUE ET DE SANTE (EDS) [Internet]. Institut National de la Statistique du Mali|INSTAT. [cité 7 juin 2022]. Disponible sur: https://www.instat-mali.org/fr/publications/enquete-demographique-et-de-sante-eds
IV. WHO | WHO Global Surveillance and Monitoring System [Internet]. WHO. [cité 27 nov 2020]. Disponible sur: http://www.who.int/medicines/regulation/ssffc/surveillance/en/
V. Handbook_of_training_materials_SF_French.pdf [Internet]. [cité 30 déc 2021]. Disponible sur: https://www.who.int/medicines/regulation/ssffc/mechanism/Handbook_of_training_materials_SF_French.pdf
VI. Pitts A. Guidance for Implementing Risk-based Post-marketing Quality Surveillance in Low- and Middle-income Countries. :54.
VII. MedRS | Log In [Internet]. [cité 29 déc 2021]. Disponible sur: https://medrsv2.com/
VIII. Drug Quality Promotion Program. Strengthening National Capacity in Medicine Quality: Five-Year Summary (2005-2009) of the Medicine Quality Promotion Program in Southeast Asia and the Philippines. Rockville, Md: The United States Pharmacopoeial Convention. Accessed: 09 Nov. 2018. Available at: http://www.usp-pqm.org/sites/default/files/pqms/article/rdmareport.pdf
IX. Dembélé O, Coulibaly S, Cissé B, Cissé M, Dakouo J, Cissé N, et al. Risk-Based Post-Marketing Surveillance (RB-PMS) of antimalarial drugs and maternal, neonatal and reproductive health (MNCH) in Mali. Journal of Drug Delivery and Therapeutics. 7 mars 2022;12:6‑10.
X. Dembélé O, Coulibaly S, Dakouo J, Koumaré B. PRE- AND POST-MARKETING CONTROL OF DRUG QUALITY AT THE NATIONAL HEALTH LABORATORY, BAMAKO-MALI. Universal Journal of Pharmaceutical Research. 15 janv 2022;
XI. Dembélé O, Cissé B, Cissé M, Coulibaly S, Dakouo J, Cissé N, et al. Evaluation of the quality of the main antimicrobial drugs sold in pharmacies in Bamako (Mali) according to a risk-based sampling. Journal of Drug Delivery and Therapeutics. 15 juin 2022;12:154‑9.
XII. A Sidibé O. Quality control of medicines antimalarials in seven (07) administratives regions of Mali and Bamako district: operationalization of minilab kits. Published online 2012. Accessed April 2, 2021.